Option chain shows key data for Sandoz Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sandoz Group.

Sandoz Group (OTC:SDZNY) Stock, Option Chain

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG

WIIM

Ford shares are trading higher. On Thursday, the UAW makes huge inroads at Ford Battery Plant.

Ratings for Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ameren, revealing an average target of $89.71, a high estimate of $97.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 6.58% increase from the previous average price target of $84.17.
<img src="https://www.benzinga.com/files/images/story/2024/1732305924_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Ameren is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Neil Kalton</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$89.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ameren. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ameren compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ameren's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ameren's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AEE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ameren analyst ratings.</a>
<h2>Discovering Ameren: A Closer Look</h2>
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves more than 2.4 million electricity customers and more than 900,000 natural gas customers.
<h3>Ameren: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Ameren's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.49% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: Ameren's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.98%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ameren's ROE excels beyond industry benchmarks, reaching 3.9%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ameren's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: Ameren's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For Ameren

News

TMUS

FCC's $8B Phone Subsidy Will Get Supreme Court Scrutiny

In the latest quarter, 6 analysts provided ratings for Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Expand Energy and provided 12-month price targets. The average target is $97.17, accompanied by a high estimate of $116.00 and a low estimate of $85.00. Surpassing the previous average price target of $91.83, the current average has increased by 5.82%.
<img src="https://www.benzinga.com/files/images/story/2024/1732305763_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Expand Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Paul Diamond</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$89.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Expand Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Expand Energy compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Expand Energy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Expand Energy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Expand Energy analyst ratings.</a>
<h2>Unveiling the Story Behind Expand Energy</h2>
Expand Energy Corp independent natural gas producer in the United States. It is fueling a more affordable, reliable, and lower-carbon future. The group focused on developing abundant natural gas, oil, and gas liquids to expand energy access.
<h3>Expand Energy: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Expand Energy's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -57.28%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Expand Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17.65%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Expand Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.11%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.84%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Expand Energy's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Expand Energy

Petrobras shares are trading higher after its board approved $3.4B in extraordinary dividends

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Agilent Technologies to report an earnings per share (EPS) of $1.40.
Investors in Agilent Technologies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 0.16% increase in the share price the next day.
Here's a look at Agilent Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.26</td>
<td>1.19</td>
<td>1.22</td>
<td>1.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.22</td>
<td>1.29</td>
<td>1.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732305703_0.png" alt="eps graph" />
<h3>Market Performance of Agilent Technologies's Stock</h3>
Shares of Agilent Technologies were trading at $132.06 as of November 21. Over the last 52-week period, shares are up 5.86%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about Agilent Technologies</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Agilent Technologies.
Analysts have provided Agilent Technologies with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $149.0, suggesting a potential 12.83% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of IQVIA Hldgs, Waters and Illumina, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for IQVIA Hldgs, with an average 1-year price target of $261.21, implying a potential 97.8% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Waters, with an average 1-year price target of $370.0, implying a potential 180.18% upside.</li>
<li>For Illumina, analysts project an Neutral trajectory, with an average 1-year price target of $173.56, indicating a potential 31.43% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for IQVIA Hldgs, Waters and Illumina, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$855M</td>
<td>4.65%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Outperform</td>
<td>4.28%</td>
<td>$1.38B</td>
<td>4.17%</td>
</tr>
<tr>
<td>Waters</td>
<td>Neutral</td>
<td>4.02%</td>
<td>$438.65M</td>
<td>10.71%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-3.49%</td>
<td>$745M</td>
<td>39.60%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Agilent Technologies ranks in the middle among peers for Consensus rating. It is at the bottom for Revenue Growth. For Gross Profit, it is at the top. In terms of Return on Equity, Agilent Technologies is at the bottom compared to its peers.
<h3>Delving into Agilent Technologies's Background</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Agilent Technologies's revenue growth over a period of 3 months has faced challenges. As of 31 July, 2024, the company experienced a revenue decline of approximately -5.62%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agilent Technologies's net margin excels beyond industry benchmarks, reaching 17.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Agilent Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 4.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Agilent Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.58%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/A/earnings">To track all earnings releases for Agilent Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What's Next: Agilent Technologies's Earnings Preview

For the first time in years, the U.S. is witnessing a sustained decline in overdose deaths. Federal data reveals a 14.5% drop in fatalities over 12 months ending June 2024, marking a significant shift after years of grim records. Experts attribute the change to a combination of expanded <a href="https://www.benzinga.com/markets/cannabis/24/06/39470316/un-health-officials-new-report-calls-for-end-to-drug-war-harm-reduction-scientific-approach-to-d">harm reduction</a> efforts, increased accessibility to treatment and changes in the illicit drug supply itself.
<h3 class="wp-block-heading">Drivers Behind Decline In Overdose Deaths </h3>
According to a recent <a href="https://www.nytimes.com/2024/11/21/health/overdose-deaths-decline-drug-supply.html">article</a> in The New York Times, weakened fentanyl potency has played a critical role. Anne Milgram, head of the Drug Enforcement Administration (DEA), <a href="https://www.dea.gov/press-releases/2024/11/15/deas-third-annual-national-family-summit-fentanyl-highlights-progress">announced</a> a decline in fentanyl potency for the first time since 2021. The DEA linked this shift to crackdowns on Mexican cartels and international supply chains.
Another notable factor is evolving drug use behavior. Increasingly, users are smoking or snorting fentanyl to avoid necrotic wounds caused by xylazine, <a href="https://www.benzinga.com/markets/cannabis/23/04/31788751/biden-administration-calls-fentanyl-laced-with-xylazine-emerging-threat-what-now">an animal tranquilizer often mixed with fentanyl</a>. This shift, though not necessarily safer, reflects growing awareness of harm reduction messaging.
<h3 class="wp-block-heading">Combating Overdoses With A Pragmatic Approach</h3>
Harm reduction programs, such as <a href="https://www.benzinga.com/markets/cannabis/23/03/31549189/fda-approves-over-the-counter-sale-of-opioid-reversal-drug-narcan">wider distribution of naloxone</a> (Narcan), fentanyl test strips and syringe exchanges, have further contributed to the decline.
Additionally, more states now prescribe medications to suppress opioid cravings. Programs providing sterile syringes and community education further empower users to <a href="https://www.benzinga.com/markets/cannabis/24/07/39912563/exclusive-this-new-harm-reduction-group-wants-home-testing-kits-available-for-all-drugs">take precautions</a> against <a href="https://www.benzinga.com/markets/cannabis/24/09/40990399/fentanyl-laced-with-toxic-chemical-btmps-raises-alarms-nationwide-experts-warn-of-danger">dangerous adulterants</a>.
<h3 class="wp-block-heading">Racial Disparities In Overdose Deaths Death Rise</h3>
However, while these developments are promising, <a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">overdose death rates among Black and Indigenous Americans are still rising</a>. Limited access to public health services in marginalized communities underscores a growing racial disparity.&nbsp;
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
Eastern and Midwestern states have seen sharper declines, possibly due to more seasoned responses to fentanyl. In contrast, overdose deaths are still rising in some Western states where fentanyl arrived later.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise</a>
<h3 class="wp-block-heading">Communities Still Struggling With Ongoing Crisis</h3>
Despite the progress, policymakers caution against complacency as fatalities remain alarmingly high, with overdose deaths exceeding 97,000 in 2024. "There are entire communities that are not seeing that progress. Many families continue to be impacted by it every day," said Dr. Allison Arwady of the Centers for Disease Control and Prevention (CDC), according to The NY Times.
As the U.S. continues to grapple with the overdose crisis, experts stress the need for sustained prevention efforts and addressing systemic disparities in access to treatment and resources.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39912563/exclusive-this-new-harm-reduction-group-wants-home-testing-kits-available-for-all-drugs">EXCLUSIVE: This New Harm Reduction Group Wants Home Testing Kits Available For All Drugs</a></li>
</ul>
Image generated with AI tools.

Cannabis

Health Care

US Overdose Deaths Decline As Fentanyl Potency Weakens, Harm Reduction Expands

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid continued momentum.

<a href="https://x.com/saylor/status/1860049786285826307" title="https://x.com/saylor/status/1860049786285826307">https://x.com/saylor/status/1860049786285826307</a>

Trading Ideas

MARA

MSTR

Watching Shares Of MARA Holdings; MicroStrategy Chairman Michael Saylor Posting On X, "$MARA is a company on the #Bitcoin Standard."

Cryptocurrency markets are trading higher, with Bitcoin hovering around $100,000 and <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42144871/jim-cramer-says-own-bitcoin-thats-a-winner-crypto-community-scoffs-pack-up-your-bags-sell-everything">Jim Cramer suggesting it is &#8220;a winner</a>.&#8221;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$99,254.71</td>
<td>+0.88%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,281.28</td>
<td>-2.1%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$253.09</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3987</td>
<td>+3.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002463</td>
<td>+0.3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 47.5% and daily active addresses growing by 27.2%. Transactions greater than $100,000 are up from 13,321 to 18,859 in a single day. Exchanges netflows are down by 4.5%.</li>
<li>Coinglass data reports 113,608 traders were liquidated in the past 24 hours for $340.73 million. Open interest continues to stand at peak levels, $64 billion.</li>
<li>Polymarket <a href="https://polymarket.com/markets/crypto/crypto-prices">data</a> shows there is a 60% chance of Bitcoin touching $100,000 today and an 89% probability of it happening this month.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42124007/trump-media-trademark-filing-for-truthfi-hints-at-potential-digital-wallets-asset-trading">Trump Media Trademark Filing For &#8216;TruthFi&#8217; Hints At Potential Digital Wallets, Asset Trading</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136031/charles-schwab-prepares-for-spot-cryptocurrency-trading-under-new-leadership">Charles Schwab Prepares For Spot Cryptocurrency Trading Under New Leadership</a></li>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42142397/trump-medias-truthfi-gamble-tests-bulls-and-bears">Trump Media&#8217;s TruthFi Gamble Tests Bulls And Bears</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42143918/strike-ceo-jack-mallers-bitcoin-is-the-best-performing-asset-in-the-history-of-mankind">Strike CEO Jack Mallers: &#8216;Bitcoin Is The Best Performing Asset In The History Of Mankind&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">Solana Hits $264 Record High As ETF Filings, Regulatory Optimism Drive Market Momentum</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>)</td>
<td>$0.3194</td>
<td>+28.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$1.42</td>
<td>+20.6%</td>
</tr>
<tr>
<td>Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>$0.9647</td>
<td>+19.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Bitcoin nearing $100,000 sparked mixed sentiments among traders. 
Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1859959484438970634">quipped</a> "See you guys at $60,000" when Bitcoin failed to break through the psychological barrier.
Crypto trader Seth highlights a "thick and sticky sell wall" as the obstacle.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The menace right now! This is a thick and sticky sell wall. &#x1f972;<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/w25TFe6gev">https://t.co/w25TFe6gev</a> <a href="https://t.co/13uVxevS9T">pic.twitter.com/13uVxevS9T</a>
&mdash; Seth (@seth_fin) <a href="https://twitter.com/seth_fin/status/1860030191172751682?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin founder Billy Markus <a href="https://x.com/BillyM2k/status/1860031634218844543">stated</a>, "maybe bitcoin will become a $99,000 stablecoin."
Quinten Francois remains optimistic, stating the Bitcoin bull market has "just started."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The bull market just started &#x1f440;&#x1f4a5; <a href="https://t.co/QYfxyaKAeJ">pic.twitter.com/QYfxyaKAeJ</a>
&mdash; Quinten &#x7C; 048.eth (@QuintenFrancois) <a href="https://twitter.com/QuintenFrancois/status/1860034071507976659?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1860037119575458134">explained</a> that traders are preemptively shifting from altcoins to Bitcoin as it edges closer to the $100,000 milestone. 
He predicts a breakout, followed by consolidation could lead to altcoin rebounds. Until then, Bitcoin is expected to continue absorbing liquidity.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42142159/bitcoin-paying-for-your-mortgage-one-company-enables-it-but-theres-a-catch">Bitcoin Paying For Your Mortgage? One Company Enables It, But There&#8217;s A Catch</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XLM

$XRP

Bitcoin 'On Brink Of Breaking $100,000,' Dogecoin Up, Ethereum Down: Crypto Community Holds Its Breath As BTC Guns For Milestone

Needham analyst Tom Nikic initiated coverage on Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Buy rating and <a href="https://www.benzinga.com/quote/FL/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $27</a>.
The analyst writes that Foot Locker is positioned for an earnings recovery in 2025, with improvements expected from a strengthened Nike, Inc partnership, growth in non-Nike brands, recent SG&amp;A investments, and the recovery of merchandise margins.
Despite a current lull post-back-to-school, the analyst expects trends to pick up after Thanksgiving and is encouraged by a recent consumer survey indicating strong holiday interest in sneakers.
Nikic notes that Foot Locker faced challenges due to Nike&#8217;s decision to reduce high-demand product supply but believes Nike&#8217;s shift to increase product allocations to Foot Locker starting in the fourth-quarter of 2024 will drive positive sales growth.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/42144102/california-has-the-finest-weed-in-the-world-says-lab-expert-and-how-to-save-its-struggling-market" rel="noreferrer noopener">California Has The Finest Weed In The World, Says Lab Expert, And How To Save Its Struggling Market</a>
Additionally, Foot Locker is benefiting from expanding Hoka and On availability, along with strengthened relationships with brands like Adidas AG, New Balance, Crocs, Inc., and UGG.
The analyst explains that Foot Locker&#8217;s EBIT margin was significantly lower last year compared to pre-COVID levels and is only expected to see modest improvement in FY24 due to aggressive long-term growth investments.
However, as spending tapers off next year, Foot Locker is expected to leverage these investments to expand margins.
Additionally, with merchandise margins still over 300bps below pre-COVID levels, there is further opportunity for gross margin improvement, Nikic adds.
The analyst projects the company to report FY24 revenues of $8.164 billion and earnings per share of $1.61.
Price Action: FL stock is up 1.67% at $22.83 at last check Friday.
Photo by Sorbis via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize" target="_blank" rel="noreferrer noopener">DOJ Targets Google Chrome, Poll Shows 64% Oppose Alphabet Breakup: YouTube Seen As Top Prize</a></li>
</ul>

Analyst Color

Equities

Price Target

Initiation

General

ADDYY

CROX

Foot Locker To Gain From Strengthened Partnership With Nike: Analyst Forecasts Earnings Recovery Next Year

Offerings

Citizens Inc. Files Prospectus For Up To 5M Shares Of Co's Class A Common Stock Under Stock Investment Plan

<a href="https://www.cpsc.gov/Recalls/2023/YETI-Recalls-1-9-Million-Soft-Coolers-and-Gear-Cases-Due-to-Magnet-Ingestion-Hazard" title="https://www.cpsc.gov/Recalls/2023/YETI-Recalls-1-9-Million-Soft-Coolers-and-Gear-Cases-Due-to-Magnet-Ingestion-Hazard">https://www.cpsc.gov/Recalls/2023/YETI-Recalls-1-9-Million-Soft-Coolers-and-Gear-Cases-Due-to-Magnet-Ingestion-Hazard</a>

YETI

'YETI Recalls 1.9 Million Soft Coolers and Gear Cases Due to Magnet Ingestion Hazard' -CPSC

Whales with a lot of money to spend have taken a noticeably bullish stance on Intel.
Looking at options history for Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $89,850 and 12, calls, for a total amount of $430,148.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $55.0 for Intel, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Intel's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intel's whale activity within a strike price range from $3.0 to $55.0 in the last 30 days. 
<h3>Intel Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732304818_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$7.15</td>
<td>$7.15</td>
<td>$25.00</td>
<td>$71.5K</td>
<td>3.9K</td>
<td align="right">106</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.5</td>
<td>$29.9</td>
<td>$30.5</td>
<td>$55.00</td>
<td>$64.0K</td>
<td>107</td>
<td align="right">21</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.68</td>
<td>$20.00</td>
<td>$56.8K</td>
<td>5.2K</td>
<td align="right">100</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$21.95</td>
<td>$21.6</td>
<td>$21.9</td>
<td>$3.00</td>
<td>$43.8K</td>
<td>678</td>
<td align="right">24</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$22.5</td>
<td>$21.5</td>
<td>$21.79</td>
<td>$3.00</td>
<td>$32.6K</td>
<td>678</td>
<td align="right">44</td>
</tr>
</tbody>
</table>

<h3>About Intel</h3>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
Following our analysis of the options activities associated with Intel, we pivot to a closer look at the company's own performance.
<h3>Current Position of Intel</h3>
<ul>
<li>With a volume of 19,803,350, the price of INTC is up 0.35% at $24.52. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

INTC

Intel Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Wells Fargo.
Looking at options history for Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $459,983 and 6, calls, for a total amount of $1,644,858.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $105.0 for Wells Fargo during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Wells Fargo's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Wells Fargo's whale trades within a strike price range from $70.0 to $105.0 in the last 30 days. 
<h3>Wells Fargo Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732304812_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.62</td>
<td>$2.58</td>
<td>$2.6</td>
<td>$77.50</td>
<td>$1.0M</td>
<td>10.1K</td>
<td>4.1K</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.63</td>
<td>$1.65</td>
<td>$80.00</td>
<td>$430.2K</td>
<td>15.4K</td>
<td>2.6K</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.25</td>
<td>$9.05</td>
<td>$9.05</td>
<td>$72.50</td>
<td>$161.9K</td>
<td>793</td>
<td>179</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.15</td>
<td>$29.35</td>
<td>$29.97</td>
<td>$105.00</td>
<td>$149.8K</td>
<td>100</td>
<td>50</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$4.92</td>
<td>$80.00</td>
<td>$98.4K</td>
<td>222</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About Wells Fargo</h3>
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
After a thorough review of the options trading surrounding Wells Fargo, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Wells Fargo's Current Market Status</h3>
<ul>
<li>Trading volume stands at 6,445,834, with WFC's price up by 1.14%, positioned at $75.68.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
<h3>What Analysts Are Saying About Wells Fargo</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $79.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Wells Fargo, which currently sits at a price target of $82. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Wells Fargo with a target price of $77. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wells Fargo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at Wells Fargo's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bearish stance on Occidental Petroleum.
Looking at options history for Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $146,300 and 6, calls, for a total amount of $255,160.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $55.0 for Occidental Petroleum over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Occidental Petroleum's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Occidental Petroleum's substantial trades, within a strike price spectrum from $50.0 to $55.0 over the preceding 30 days.
<h3>Occidental Petroleum 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732304807_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$50.00</td>
<td>$69.0K</td>
<td>9.7K</td>
<td>255</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.4</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$55.00</td>
<td>$63.5K</td>
<td>1.0K</td>
<td>106</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$2.75</td>
<td>$2.68</td>
<td>$2.69</td>
<td>$50.00</td>
<td>$53.8K</td>
<td>452</td>
<td>411</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.49</td>
<td>$0.46</td>
<td>$0.47</td>
<td>$55.00</td>
<td>$47.0K</td>
<td>18.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.5</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$55.00</td>
<td>$31.0K</td>
<td>2.9K</td>
<td>73</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,234 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
In light of the recent options history for Occidental Petroleum, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Occidental Petroleum</h3>
<ul>
<li>With a trading volume of 4,452,147, the price of OXY is up by 0.61%, reaching $51.85.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Occidental Petroleum</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $65.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on Occidental Petroleum, which currently sits at a price target of $65. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Occidental Petroleum, targeting a price of $78. 
&#x2A; An analyst from Stephens &amp; Co. has decided to maintain their Overweight rating on Occidental Petroleum, which currently sits at a price target of $71. 
&#x2A; An analyst from JP Morgan downgraded its action to Neutral with a price target of $56. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Occidental Petroleum, which currently sits at a price target of $58. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Occidental Petroleum options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

What the Options Market Tells Us About Occidental Petroleum

<a href="https://www.theglobeandmail.com/business/article-us-investor-bill-ackman-acquires-26-billion-stake-in-brookfield-corp/" title="https://www.theglobeandmail.com/business/article-us-investor-bill-ackman-acquires-26-billion-stake-in-brookfield-corp/">https://www.theglobeandmail.com/business/article-us-investor-bill-ackman-acquires-26-billion-stake-in-brookfield-corp/</a>

Insider Trades

U.S. Investor Bill Ackman Acquires $2.6B Stake In Brookfield Corp- Globe And Mail

For over 30 years before the COVID-19 pandemic, investors thrived during what is often referred to as the Great Moderation. Despite a painful episode with the Great Recession, this period saw relatively stable economic conditions, with <a href="https://www.benzinga.com/topic/inflation">fewer recessions, lower inflation</a>, and diminished volatility.
The rise of globalization and free trade during this era provided corporations access to cheaper labor and production resources, bolstering profits and encouraging growth. However, according to Liz Ann Sonders, chief investment strategist at Charles Schwab, this <a href="https://www.schwab.com/learn/story/is-next-temperamental-era-upon-us">stability era</a> has ended. Sonders has coined the current phase the &#8216;Temperamental Era,&#8217; a period she likens to the volatile economic landscape of the mid-1960s through the early 1990s.
Sonders sees this era as one with increased volatility in economic performance and inflation. Since 2020, dramatic swings in GDP growth have become commonplace, with sharp contractions followed by rapid rebounds—similar to the patterns seen in the latter half of the 20th century.
Inflation has also become more volatile, reminding economists of the 1970s. Back then, the Federal Reserve declared victory over inflation prematurely, leading to policy missteps and back-to-back recessions in the early 1980s. Sonders notes that the current environment is similarly characterized by uncertainty in inflation trends, accompanied by ongoing supply chain reconfigurations and geopolitical tensions.
As companies move toward nearshoring or regional diversification, they drive a shift in supply chain management. Although this strategy enhances resilience, it also raises production costs due to limited regional capacities. Meanwhile, the re-emergence of geopolitical rivalries, particularly between the U.S. and China, and NATO and Russia, causes tensions, increasing the likelihood of trade restrictions, tariffs, and supply risks, further fueling inflationary pressures.
Also Read: <a href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst">&#8216;Staggering&#8217; Google Breakup Proposal From DOJ A &#8216;Kitchen Sink Moment&#8217;: Alphabet Analyst</a>
ING's research last year <a href="https://www.ing.com/Newsroom/News/Inflations-second-wave-Are-we-really-watching-a-70s-rerun.htm">found</a> that while a repeat of the 1970s inflationary crisis is not inevitable, the risks of higher and more volatile inflation and central bank rates over the next decade are significant.
Shortages of key materials, partly driven by the green energy transition and geopolitical conflicts, could exert upward pressure on prices. Additionally, worker power gradually increases due to labor shortages, pushing wages upward. Accompanied by tighter fiscal and monetary policies designed to curb inflation, the environment limits the flexibility of governments and central banks to respond to future crises.
For investors, this new era demands a shift in strategy. The low-interest-rate environment of the Great Moderation enabled even weak companies to survive on cheap borrowing, but that era is over. Instead, Charles Schwab sees the importance of focusing on fundamentals when selecting stocks.
They note price-to-cash flow, price momentum, and return volatility as metrics of interest. Price-to-cash flow helps investors gauge a company's ability to sustain operations and meet financial obligations. Price momentum identifies stocks with favorable trends, as past performance often predicts short-term direction. Lastly, return volatility (Beta) measures the stability of a stock's price movements, with lower volatility typically signaling a less risky investment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Opinion

Why Volatility Is The New Normal: From Great Moderation To 'Temperamental Era'

Wall Street analysts rerated Gap, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) after the company reported upbeat third-quarter print Thursday.
The <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/42141895/whats-going-on-with-gap-shares-friday" rel="noreferrer noopener">company reported sales</a> of $3.829 billion, beating analyst consensus of $3.812 billion. Earnings per share of 72 cents topped analyst estimates of 57 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch" rel="noreferrer noopener">Amazon Strengthens Anthropic Partnership with $8 Billion AI Investment</a>
It now expects fiscal 2024 revenue of $15.124 billion &#8211; $15.198 billion, above the consensus of $14.956 billion.
BMO Capital analyst Simeon Siegel maintained Gap with a Market Perform and raised the <a target="_blank" href="https://www.benzinga.com/quote/GAP/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$23&nbsp;to&nbsp;$25</a>.
Telsey Advisory Group analyst Dana Telsey reiterated Gap with a Market Perform and a $26&nbsp;price target.
BofA Securities analyst Lorraine Hutchinson maintained Gap with a Neutral and raised the price target from&nbsp;$25&nbsp;to&nbsp;$28.
Guggenheim analyst Robert Drbul reiterated a Buy rating on Gap with a price target of $35.
BMO Capital: Gap reported third-quarter EPS that significantly exceeded expectations, with sales slightly surpassing estimates.
Key drivers included robust gross margin improvement, supported by more substantial merchandise margins and ROD leverage. Banana Republic, Gap, and Athleta exceeded expectations, while Old Navy met projections despite weather-related challenges. Management highlighted market share gains across all brands and raised its guidance for full-year sales, gross margin, and EBIT growth.
Old Navy sales were flat year-over-year, marking a moderation from prior quarters but maintaining momentum. Unseasonably warm weather impacted the performance of children&#8217;s apparel, but sales rebounded as weather patterns normalized.
Gap Brand delivered its fourth consecutive quarter of positive comparable sales, growing 3% year-over-year, driven by strong product and marketing execution.
Banana Republic experienced 2% year-over-year growth, with continued emphasis on improving fundamentals and success in the men&#8217;s category.
Athleta achieved its most robust growth in two years, with sales increasing 4% year-over-year. New product launches and marketing resonated with customers, driving share gains.
Gap&#8217;s gross margin reached 42.7%, exceeding the Street&#8217;s 42.1% estimate, with a 140-basis-point year-over-year expansion. 90-basis-point merchandise margin growth and operating leverage were key contributors. However, fourth-quarter gross margins are expected to remain flat when adjusted for ROD deleverage from calendar shifts.
Telsey Advisory Group: Telsey provided a detailed assessment of Gap following its third-quarter earnings report. The company exceeded expectations across multiple metrics, reflecting strong operational discipline under its new leadership.
Gap has demonstrated clear progress under its strategic focus on operational discipline, inventory efficiency, and brand portfolio growth. However, the analyst cautions that sustained consistency in performance and long-term profitability will be critical for investor confidence. The positive momentum in sales and profitability efforts suggests Gap is stabilizing its business and positioning itself for future growth.
The price target is based on an 11.5x multiple of the two-year forward EPS estimate of $2.26. While this valuation is slightly below Gap&#8217;s historical average of 13.1x, it reflects the company&#8217;s ongoing challenges in a competitive retail environment.
BofA Securities: Hutchinson highlighted its sales and margin performance while cautioning about future margin expansion.
Gap delivered adjusted EPS of $0.72, outperforming Hutchinson&#8217;s estimate of $0.54 and the consensus projection of $0.57. The beat was supported by 1.6% sales growth, gross margin improvement, and effective SG&amp;A management. Comps were positive at Athleta (+5%) and Gap (+3%). Management raised its fiscal 2024 guidance, reflecting the third-quarter outperformance.
Hutchinson raised fiscal 2024 and fiscal 2025 EPS estimates by 9% and 5%, respectively, projecting $1.97 and $1.99. The analyst increased the price target to $28, based on a 6x 2025 estimated EV/EBITDA.
Management raised its fiscal 2024 guidance for sales, gross margin, and operating income. Hutchinson expects gross margin to improve by 350 basis points compared to 2019, driven by reduced promotions and more vital full-price selling.
However, Hutchinson highlighted that while Gap has achieved significant cost savings, management may prioritize reinvesting efficiencies into growth initiatives and inflation offsets rather than improving the bottom line.
Hutchinson&#8217;s price target of $28 reflects a 6x 2025 estimated EV/EBITDA, consistent with peer averages. This valuation balances risks tied to Gap&#8217;s exposure to low-income consumers and freight costs against its turnaround potential and Athleta&#8217;s relatively more robust performance.
While Hutchinson acknowledges the company&#8217;s improved sales trajectory, remains cautious on further margin growth.
Guggenheim: Drbul highlighted the company&#8217;s earnings beat, strategic progress, and upwardly revised guidance. The quarter marked the company&#8217;s fourth consecutive quarter of top-line growth and seventh quarter of market share gains.
Drbul values Gap at 15.2x 2025 EPS, a premium to its five-year average multiple of 12.5x, reflecting confidence in ongoing operational improvements and growth potential.
He highlighted the strength of the Old Navy and Athleta brands as critical drivers, particularly noting Athleta&#8217;s position in an attractive apparel segment. With a ~3% dividend yield, Drbul views Gap shares as offering a compelling risk-reward profile supported by significant asset value and strategic optionality.
Drbul&#8217;s price target underscores optimism about Gap&#8217;s ability to sustain its momentum, deliver margin expansion, and execute its reinvigoration initiatives successfully.
Price Action: GAP stock is up 11.2% at $24.51 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42140725/snap-denies-facilitating-child-exploitation-seeks-dismissal-of-state-lawsuit" target="_blank" rel="noreferrer noopener">Snap Denies Child Exploitation Allegations, Wants Lawsuit Dismissed</a></li>
</ul>

Reiteration

Gap's Growth Drivers: Market Share Gains, Brand Momentum, And Raised Guidance – Analysts Weigh In

A recent study <a href="https://www.nature.com/articles/s41598-024-79931-w">published</a> in Scientific Reports explores the strategies individuals use to navigate challenging psychedelic experiences and how these responses relate to emotional breakthroughs. Researchers from University College London conducted a mixed-methods investigation, combining qualitative analyses of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> retreat participants&#8217; experiences with a broader survey involving 529 individuals who reported past psychedelic use.
<h3 class="wp-block-heading">Three Core Strategies Identified</h3>
The study developed the Responses to Challenging Psychedelic Experiences Inventory (ReCiPE), revealing three key coping strategies:
<ul>
<li>Acceptance and Reappraisal: Emphasizing surrender and acceptance of the experience, this approach was most strongly associated with emotional breakthroughs.</li>
<li>Sensory Regulation and Physical Interaction: Strategies such as intentional breathing, movement or environmental engagement helped participants manage distress.</li>
<li>Social Support and Disclosure: Seeking help or sharing experiences with others proved beneficial, reinforcing the role of interpersonal dynamics during challenging moments.</li>
</ul>
<h3 class="wp-block-heading">Fear Vs. Breakthroughs</h3>
The research found that not all challenges led to positive outcomes. Fear-related experiences often hindered emotional breakthroughs, whereas grief and death-related challenges were more likely to result in transformative insights. This suggests that the type of distress experienced during a psychedelic session plays a significant role in determining therapeutic outcomes. 
See also: <a href="https://www.benzinga.com/markets/cannabis/23/06/32800473/psychedelic-trip-dos-and-donts-what-to-avoid-during-your-psychedelic-experience">Psychedelic Trip Do&#8217;s And Don&#8217;ts: What To Avoid During Your Psychedelic Experience</a>
<h3 class="wp-block-heading">Implications For Psychedelic-Assisted Therapy</h3>
The findings highlight the importance of equipping individuals with adaptive coping strategies, particularly through acceptance-based approaches such as mindfulness or Acceptance and Commitment Therapy. Tailored interventions that address fear and promote cognitive reappraisal could enhance the safety and efficacy of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapies</a>.
As the study authors conclude, "The paradoxical positive therapeutic role of challenging psychedelic experiences may depend on the kind of challenge faced and the individual's ability to employ adaptive response strategies."
Cover image made with AI

Psychedelics

How To Navigate Difficult Psychedelic Journeys: Research Insights

JPMorgan raised the firm's price target on Sandoz (SDZNY) to CHF 43 from CHF 36.50 and keeps an Overweight rating on the shares. Published first on...

Sandoz price target raised to CHF 43 from CHF 36.50 at JPMorgan

FDA accepts Organon BLA for Prolia/Xgeva biosimilar

Morgan Stanley raised the firm's price target on Sandoz (SDZNY) to CHF 35 from CHF 32 and keeps an Equal Weight rating on the shares. Published fir...

Sandoz price target raised to CHF 35 from CHF 32 at Morgan Stanley

RBC Capital raised the firm's price target on Sandoz (SDZNY) to CHF 42 from CHF 40 and keeps a Sector Perform rating on the shares. Published first...

Sandoz price target raised to CHF 42 from CHF 40 at RBC Capital

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on Sandoz Group Ltd (SDZXF – Research Report) on October 30 and set a price target ...

Sandoz Group Ltd (SDZXF) Gets a Buy from Kepler Capital

Berenberg raised the firm's price target on Sandoz (SDZNY) to CHF 39 from CHF 38 and keeps a Hold rating on the shares. Published first on TheFly –...

Sandoz price target raised to CHF 39 from CHF 38 at Berenberg

Deutsche Bank raised the firm's price target on Sandoz (SDZNY) to CHF 36 from CHF 33 and keeps a Hold rating on the shares. Published first on TheF...

Sandoz price target raised to CHF 36 from CHF 33 at Deutsche Bank

Artisan International Value Fund Q3 2024 Commentary

Artisan Global Discovery Fund Q3 2024 Commentary

Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe f...

Sandoz receives EC approval for Afqlir

ACGL

ALVO

AMGN

ANCTF

ARGNF

ARGX

ARMK

BABA

BABAF

CHYHY

CMPGF

CMPGY

COHR

CRTSF

CWAN

ESTC

GALDY

GDERF

GRRMF

GRRMY

GWRE

HUBB

HXSCF

IRTC

MPWR

MTSI

NVSEF

NVZMF

NVZMY

ONTO

PLXNF

RYLPF

SDXAY

SDXOF

SDZNY

SDZXF

SSNLF

SVNDF

SVNDY

TCOM

TREX

TTEK

TTNDF

TTNDY

UNLYF

VEEV

VWDRY

VWSYF

WING

Screenshot 2024-10-01 at 5.30.51 PM

Biotech

Psilocybin&#39;s Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Press Releases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz Group

Comments

Sandoz Group

Sandoz Group (SDZNY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga